A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicentre, non-inferiority, phase II/III clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) of M/s Serum Institute of India Limited in healthy infants

Trial Profile

A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicentre, non-inferiority, phase II/III clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) of M/s Serum Institute of India Limited in healthy infants

Completed
Phase of Trial: Phase II/III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Diphtheria tetanus and pertussis vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 21 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top